BioSpace News Archive

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2024 financial results and business updates.

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2024.

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2024.

Pulse Biosciences, Inc., a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ technology, announced enhancements to its executive leadership team to support its next pivotal phase of growth.

NeuroSense Therapeutics announced that it partnered with PhaseV, a pioneer in causal machine learning for clinical trial analysis and optimization, with respect to the planned Phase 3 trial of PrimeC as a treatment for amyotrophic lateral sclerosis.

Multiply Labs and Retro Biosciences announced a first-of-its-kind commercial and supply agreement valued at up to $85 million to automate Retro’s groundbreaking approach.

Merit Medical Systems, Inc., a global leader of healthcare technology, announced US Food and Drug Administration 510 clearance for its Siege Vascular Plug. Merit also announced the launch of its Bearing nsPVA Express Prefilled Syringe in the United States and Australia.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical

Nurix Therapeutics, Inc. announced an upcoming oral presentation highlighting new clinical data from Nurix’s orally available, selective BTK degrader, NX-5948, at the European Hematology Association Congress which is being held from June 13 - 16, 2024, in Madrid, Spain, and virtually.

Editas Medicine, Inc. announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel have been accepted for presentation at the European Hematology Association Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream.